Literature DB >> 15681596

Treatment outcome of angiocentric T-cell and NK/T-cell lymphoma, nasal type: radiotherapy versus chemoradiotherapy.

Kyubo Kim1, Eui Kyu Chie, Chul Woo Kim, Il Han Kim, Charn Il Park.   

Abstract

OBJECTIVE: The purpose of this study was to evaluate the treatment outcome of angiocentric T-cell and natural killer (NK)/T-cell lymphoma, nasal type.
METHODS: Between February 1989 and March 2001, 53 patients with newly diagnosed angiocentric T-cell and NK/T-cell lymphoma, nasal type involving the head and neck, were treated with radiation therapy (RT). There were 37 males and 16 females. The median age of the patients was 45 years (range 19-73). Twenty of them were treated with chemoradiotherapy (CRT), while 33 with treated with RT alone. The median follow-up period was 74 months (range 6-173).
RESULTS: The 5-year overall survival rate of all patients was 69%. CRT appeared to be inferior to RT alone in terms of 5-year overall survival, though the difference was not statistically significant (59 versus 76%, P = 0.27).
CONCLUSIONS: There was no difference in survival between RT and CRT in angiocentric T-cell and NK/T-cell lymphoma, nasal type.

Entities:  

Mesh:

Year:  2005        PMID: 15681596     DOI: 10.1093/jjco/hyi006

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  16 in total

1.  Extra-nodal natural killer/T cell lymphoma, nasal-type, treated by concurrent chemoradiotherapy.

Authors:  Nobuhiko Yoshikawa; Taisuke Inomata; Taiju Shinbo; Masatsugu Takahashi; Yasuo Uesugi; Yoshihumi Narumi
Journal:  Exp Ther Med       Date:  2010-05-01       Impact factor: 2.447

Review 2.  Treatment of localized extranodal NK/T cell lymphoma, nasal type.

Authors:  Seok Jin Kim; Won Seog Kim
Journal:  Int J Hematol       Date:  2010-11-18       Impact factor: 2.490

3.  Sinonasal T cell lymphoma: a case report.

Authors:  Deviprasad Shetty; Rajeshwari Aroor; K S Gangadhara Somayaji; Mohammed Tahir; N A Mohammad
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2011-04-10

Review 4.  Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment.

Authors:  Holbrook Kohrt; Ranjana Advani
Journal:  Leuk Lymphoma       Date:  2009-11

5.  Mediastinal single nodal relapse of a nasal NK/T cell lymphoma.

Authors:  Kyoung Hoon Rhee; Seok Chan Hong; Jeong Min An; Jooryung Huh; Ryu Jin Sook; Jin Seong Lee; Cheolwon Suh
Journal:  Korean J Intern Med       Date:  2007-09       Impact factor: 2.884

6.  Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphoma.

Authors:  Adrien Chauchet; Anne-Sophie Michallet; Françoise Berger; Isabelle Bedgedjian; Eric Deconinck; Catherine Sebban; Daciana Antal; Hubert Orfeuvre; Bernadette Corront; Tony Petrella; Maya Hacini; Marie Bouteloup; Gilles Salles; Bertrand Coiffier
Journal:  J Hematol Oncol       Date:  2012-06-08       Impact factor: 17.388

7.  A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma.

Authors:  Abeer N Abouyabis; Pareen J Shenoy; Rajni Sinha; Christopher R Flowers; Mary Jo Lechowicz
Journal:  ISRN Hematol       Date:  2011-06-16

8.  Treatment outcome of radiotherapy alone versus radiochemotherapy in IE/IIE extranodal nasal-type natural killer/T cell lymphoma: a meta-analysis.

Authors:  Tianxia Deng; Cheng Zhang; Xi Zhang; Sha Wu; Yaqi Xu; Shanshan Liu; Xinghua Chen
Journal:  PLoS One       Date:  2014-09-03       Impact factor: 3.240

9.  Sequential chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in patients with stage I/II extranodal natural killer/T-cell lymphoma, nasal type.

Authors:  Jieun Lee; Chul Yong Kim; Young Je Park; Nam Kwon Lee
Journal:  Blood Res       Date:  2013-12-24

10.  GDP (Gemcitabine, Dexamethasone, and Cisplatin) Is Highly Effective and Well-Tolerated for Newly Diagnosed Stage IV and Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.

Authors:  Jing-Jing Wang; Mei Dong; Xiao-Hui He; Ye-Xiong Li; Wei-Hu Wang; Peng Liu; Jian-Liang Yang; Lin Gui; Chang-Gong Zhang; Sheng Yang; Sheng-Yu Zhou; Yuan-Kai Shi
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.